| 2. |
- Smartt, S. J., et al.
(författare)
-
Pan-STARRS and PESSTO search for an optical counterpart to the LIGO gravitational-wave source GW150914
- 2016
-
Ingår i: Monthly notices of the Royal Astronomical Society. - : Oxford University Press (OUP). - 0035-8711 .- 1365-2966. ; 462:4, s. 4094-4116
-
Tidskriftsartikel (refereegranskat)abstract
- We searched for an optical counterpart to the first gravitational-wave source discovered by LIGO (GW150914), using a combination of the Pan-STARRS1 wide-field telescope and the Public ESO Spectroscopic Survey of Transient Objects (PESSTO) spectroscopic follow-up programme. As the final LIGO sky maps changed during analysis, the total probability of the source being spatially coincident with our fields was finally only 4.2 per cent. Therefore, we discuss our results primarily as a demonstration of the survey capability of Pan-STARRS and spectroscopic capability of PESSTO. We mapped out 442 deg(2) of the northern sky region of the initial map. We discovered 56 astrophysical transients over a period of 41 d from the discovery of the source. Of these, 19 were spectroscopically classified and a further 13 have host galaxy redshifts. All transients appear to be fairly normal supernovae (SNe) and AGN variability and none is obviously linked with GW150914. We illustrate the sensitivity of our survey by defining parametrized light curves with time-scales of 4, 20 and 40 d and use the sensitivity of the Pan-STARRS1 images to set limits on the luminosities of possible sources. The Pan-STARRS1 images reach limiting magnitudes of iP1 = 19.2, 20.0 and 20.8, respectively, for the three time-scales. For long time-scale parametrized light curves (with full width half-maximum similar or equal to 40 d), we set upper limits of M-i <= -17.2(+1.4)(-0.9) if the distance to GW150914 is D-L = 400 +/- 200 Mpc. The number of Type Ia SN we find in the survey is similar to that expected from the cosmic SN rate, indicating a reasonably complete efficiency in recovering SN like transients out to D-L = 400 +/- 200 Mpc.
|
|
| 3. |
- Hayes, A., et al.
(författare)
-
A European multicentre evaluation of detection and typing methods for human enteroviruses and parechoviruses using RNA transcripts
- 2020
-
Ingår i: Journal of Medical Virology. - : Wiley. - 0146-6615 .- 1096-9071. ; 92:8, s. 1065-1074
-
Tidskriftsartikel (refereegranskat)abstract
- Polymerase chain reaction (PCR) detection has become the gold standard for diagnosis and typing of enterovirus (EV) and human parechovirus (HPeV) infections. Its effectiveness depends critically on using the appropriate sample types and high assay sensitivity as viral loads in cerebrospinal fluid samples from meningitis and sepsis clinical presentation can be extremely low. This study evaluated the sensitivity and specificity of currently used commercial and in-house diagnostic and typing assays. Accurately quantified RNA transcript controls were distributed to 27 diagnostic and 12 reference laboratories in 17 European countries for blinded testing. Transcripts represented the four human EV species (EV-A71, echovirus 30, coxsackie A virus 21, and EV-D68), HPeV3, and specificity controls. Reported results from 48 in-house and 15 commercial assays showed 98% detection frequencies of high copy (1000 RNA copies/5 µL) transcripts. In-house assays showed significantly greater detection frequencies of the low copy (10 copies/5 µL) EV and HPeV transcripts (81% and 86%, respectively) compared with commercial assays (56%, 50%; P = 7 × 10−5). EV-specific PCRs showed low cross-reactivity with human rhinovirus C (3 of 42 tests) and infrequent positivity in the negative control (2 of 63 tests). Most or all high copy EV and HPeV controls were successfully typed (88%, 100%) by reference laboratories, but showed reduced effectiveness for low copy controls (41%, 67%). Stabilized RNA transcripts provide an effective, logistically simple and inexpensive reagent for evaluation of diagnostic assay performance. The study provides reassurance of the performance of the many in-house assay formats used across Europe. However, it identified often substantially reduced sensitivities of commercial assays often used as point-of-care tests.
|
|
